Shares of Sun Pharmaceutical Industries surged more than 9% on Monday, April 27, 2026, after the company announced plans to acquire US-based Organon & Co in a major all-cash deal valued at $11.75 billion. The announcement triggered strong investor enthusiasm, positioning the transaction as one of the largest overseas acquisitions by an Indian firm.

The stock opened higher at ₹1,632.50 on the BSE, up from its previous close of ₹1,619.95. Backed by a sharp rise in trading volumes—more than 4.6 times the usual—the stock climbed to an intraday high of ₹1,766.65, marking a gain of over 9%. It was last seen trading at ₹1,737, up ₹117.05 or 7.23%. The company’s market capitalisation stood at ₹4.16 lakh crore.

Deal Details

Sun Pharmaceutical Industries has entered into a definitive agreement to acquire all outstanding shares of Organon & Co at $14 per share in an all-cash transaction. Organon, which was spun off from Merck & Co. (known as MSD outside the US and Canada) in 2021, operates globally with six manufacturing facilities across the European Union and emerging markets.

Once the deal is completed, Sun Pharma is expected to rank among the world’s top 25 pharmaceutical companies, with combined revenues estimated at $12.4 billion. The acquisition will significantly strengthen its position in established brands and branded generics globally.

Among India’s Biggest Overseas Deals

This acquisition is set to join the list of landmark global buyouts by Indian companies. Notable examples include Tata Steel’s $12 billion acquisition of Corus Group in 2007, and Bharti Airtel’s $10.7 billion purchase of Zain Africa in 2010.

With this move, Sun Pharma is taking a significant step toward expanding its global footprint and strengthening its position in the international pharmaceutical market.